GlassScriptPhysician profile
Suraj S Patel
NPI 1063876704
$4,258.79
in general payments reported to CMS, 2019-2025
27 companies · $949 in 2025
The $949 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $272 · 2021: $487 · 2022: $773 · 2023: $875 · 2024: $903 · 2025: $949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,696 · Long Term Medical Supply Or Device Loan: $29.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,696.03 |
| Long Term Medical Supply Or Device Loan | $29.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $978.09 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $388.03 | 2021-2025 | Evenity, Prolia, Repatha |
| Medtronic, INC. | $371.72 | 2021-2025 | Minimed 780g |
| Sanofi-Aventis U.S. LLC | $322.01 | 2020-2023 | |
| Beta Bionics, INC. | $289.14 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Xeris Pharmaceuticals, INC. | $266.09 | 2021-2025 | Gvoke Hypopen |
| Lilly USA, LLC | $246.54 | 2021-2025 | Jardiance, Mounjaro |
| Radius Health, INC. | $209.13 | 2021-2024 | Tymlos |
| Dexcom, INC. | $166.49 | 2022-2025 | Dexcom G6 Transmitter |
| Ucb, INC. | $129.01 | 2022 | |
| Medtronic Minimed, INC. | $125.99 | 2020 | |
| Abbott Laboratories | $109.26 | 2022-2025 | Freestyle Libre 3, Freestyle Insulinx |
| Averitas Pharma INC. | $95.80 | 2023 | Qutenza |
| Insulet Corporation | $92.51 | 2022-2023 | Omnipod |
| Tandem Diabetes Care, INC. | $90.91 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $86.99 | 2025 | Penumbra System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.13 | 2021-2024 | Jardiance |
| Abbvie INC. | $52.06 | 2021-2023 | |
| Ascendis Pharma Endocrinology INC | $42.00 | 2025 | Yorvipath |
| Nevro Corp. | $30.78 | 2022 | |
| Alexion Pharmaceuticals, INC. | $19.20 | 2024 | Strensiq |
| Vivus LLC | $17.95 | 2021 | |
| Alvogen INC | $16.28 | 2025 | Teriparatide |
| Astrazeneca Pharmaceuticals LP | $15.92 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.43 | 2023 | |
| Grt US Holding, INC. | $13.20 | 2022 | |
| Merck Sharp & Dohme LLC | $11.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suraj Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.